$15M trial to clarify stem cell transplant vs. non-transplant therapy for older AML patients

For decades, older adults confronting acute myeloid leukemia have faced one of medicine's most consequential crossroads — transplant or not — armed with little more than clinical intuition and incomplete evidence. A newly funded $15 million national trial, enrolling 800 patients across 18 American medical centers, now sets out to answer what generations of oncologists could not: for which older patients does the promise of stem cell transplantation outweigh its considerable costs, and for which does a gentler path serve better. The study is as much an act of moral reckoning as scientific inqui